Don't Miss


KOL views post CheckMate-026:

NSCLC: KOL Insight


We interviewed 3 KOLs in the 7 days following the CheckMate-026 shake-up to find out how it will impact NSCLC treatment. Disappointing CheckMate-026 trial results may have sidelined Opdivo, creating a huge opportunity for rival Keytruda, and other immunotherapies.

Can one of them corner the market? Will immunotherapy combinations threaten their market share? Is there still hope for Opdivo in the first-line setting?

Hear what 3 US KOLs think in a special addendum to our new report NSCLC: KOL Insight.

Tags in Today's News

Insight, Analysis and Views

Takeda confirms plans to close UK facility: report

My News

Upgrade your subscription to get more features!

Conference News

Latest News

StoryWatch